

Treatment Period
28 days
Screening
up to 35 days
Compound I 1500 mg q12h N = 16
Compound I 300 mg q12h N = 8
Compound I 100 mg q12h N = 8
Placebo N = 8
Safety Follow-up Visit
14 and 28 days after last dose
Compound I Washout Visit
7 days after last dose

FIG. 1



Treatment Period
28 days
Screening
up to 70 days
Compound I 1500 mg q12h N = 16
Compound I 300 mg q12h N = 8
Compound I 100 mg q12h N = 8
Placebo N = 8
Safety Follow-up Visit
14 and 28 days after last dose
Discontinue augmentation therapy >42 days before AAT levels are drawn for eligibility *
Antigenic AAT level for eligibility
Compound I Washout Visit
7 days after last dose
Subjects may resume augmentation therapy after the last Safety Follow-up Visit

FIG. 2